Relmada Therapeutics, Inc.
Income Statement
| Line Item | FY2013 | FY2012 |
|---|---|---|
| Revenue | $5.1K | $7.9K |
| Cost of Revenue | $4.0K | $5.8K |
| Gross Profit | $1.1K | $2.1K |
| Gross Margin | 21.3% | 27.0% |
| Operating Expenses | ||
| Research & Development | $5.2M | $-667.5K |
| SG&A Expense | $1.5M | $-2.5M |
| Operating Income | $-6.8M | $-3.2M |
| Operating Margin | -132,071.1% | -39,752.0% |
| Interest Expense | $220.3K | $27.7K |
| Pretax Income | — | — |
| Income Tax Expense | — | — |
| Net Income | $-19.9M | $-6.9M |
| Net Margin | -387,442.2% | -86,387.5% |
| EPS (Basic) | $-40.90 | $-3.17 |
| EPS (Diluted) | $-40.90 | $-3.17 |
| Shares Outstanding (Basic) | 5.0M | — |
| Shares Outstanding (Diluted) | 5.0M | — |
| Dividends Per Share | — | — |